• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    3/25/24 2:44:08 PM ET
    $ABBV
    $AEHR
    $AKAN
    $BCAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Electrical Products
    Industrials
    Get the next $ABBV alert in real time by email

    Shares of Landos Biopharma, Inc. (NASDAQ:LABP) rose sharply during Monday’s session following acquisition news.

    AbbVie Inc. (NYSE:ABBV) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos.

    Landos Biopharma shares jumped 171.2% to $21.70 on Monday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Next.e.GO N.V. (NASDAQ:EGOX) shares jumped 85.8% to $0.0730 after falling around 22% on Friday.
    • Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares climbed 70.1% to $2.9255 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines.
    • MicroAlgo Inc. (NASDAQ:MLGO) climbed 34.3% to $5.40 after declining around 5% on Friday.
    • XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) gained 32.4% to $3.4690. XTL Biopharmaceuticals recently entered into a binding term sheet to acquire all of the issued and outstanding share capital of Social Proxy.
    • Nkarta, Inc. (NASDAQ:NKTX) gained 23.3% to $11.00 after the company priced $240 million underwritten offering.
    • Target Hospitality Corp. (NASDAQ:TH) jumped 21.3% to $10.82 after the company received a buyout offer from TDR Capital.
    • Swvl Holdings Corp. (NASDAQ:SWVL) rose 21.2% to $11.26.
    • Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) surged 21% to $0.6949.
    • Lucid Group, Inc. (NASDAQ:LCID) jumped 18.7% to $3.29 after the company announced a $1 billion investment by an affiliate of PIF.
    • Sagimet Biosciences Inc. (NASDAQ:SGMT) rose 16.9% to $5.27 after the company reported FY results and announced the appointment of Tim Walbert and Paul Hoelscher to its Board of Director.
    • Ocugen, Inc. (NASDAQ:OCGN) jumped 16.4% to $1.9101. The Third Circuit Court of Appeals recently upheld the decision of the Eastern District of Pennsylvania to dismiss with prejudice the consolidated securities class action lawsuits against Ocugen.
    • Flora Growth Corp. (NASDAQ:FLGC) shares gained 15.2% to $1.8206 after surging around 34% on Friday.
    • Forge Global Holdings, Inc. (NYSE:FRGE) shares gained 14.5% to $2.67 after gaining 13% on Friday.
    • Cipher Mining Inc. (NASDAQ:CIFR) jumped 14.1% to $5.27.
    • GoodRx Holdings, Inc. (NASDAQ:GDRX) rose 13.5% to $7.44 after Wells Fargo upgraded the stock from Equal-Weight to Overweight and announced a $10 price target.
    • Neuronetics, Inc. (NASDAQ:STIM) climbed 13.5% to $4.80. NeuroStar® Advanced Therapy received FDA clearance as a first-line add-on treatment for adolescents with depression.
    • Lichen China Limited (NASDAQ:LICN) rose 12.6% to $1.16. Lichen China announced the launch of AI-powered software - Lichen AI Robot, which was developed on GPT-based technology.
    • UroGen Pharma Ltd. (NASDAQ:URGN) rose 11.1% to $17.51.
    • Cazoo Group Ltd (NASDAQ:CZOO) gained 11% to $4.12 after declining around 21% on Friday.
    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) rose 10.5% to $0.6849 following fourth-quarter results.
    • MicroStrategy Incorporated (NASDAQ:MSTR) gained 10.3% to $1,680.00 amid strength in Bitcoin.
    • Masimo Corporation (NASDAQ:MASI) jumped 9.5% to $147.72 after the company announced it has authorized management to evaluate a proposed separation of its consumer business.
    • Foot Locker, Inc. (NYSE:FL) shares rose 8.4% to $26.45 after Evercore ISI Group upgraded the stock from In-Line to Outperform and raised its price target from $28 to $32.
    • GameStop Corp. (NYSE:GME) gained 8.2% to $14.17.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) gained 6.6% to $2.40 after the FDA approved broad labels for NEXLETOL and NEXLIZET to prevent heart attacks and cardiovascular procedures, regardless of statin use.
    • Micron Technology, Inc. (NASDAQ:MU) climbed 5.1% to $115.81.

    Losers

    • Sintx Technologies, Inc. (NASDAQ:SINT) shares fell 49.1% to $0.0471 after the company announced pricing of a $1.3 million public offering of common stock.
    • Akanda Corp. (NASDAQ:AKAN) fell 38.1% to $0.1507 after the company announced pricing of underwritten public offering.
    • Fisker Inc. (NYSE:FSR) dipped 28.1% to $0.0897 after the company announced it received notice from the large automaker with which the company had been in negotiations for a potential transaction that the automaker terminated the negotiations.
    • Australian Oilseeds Holdings Limited (NASDAQ:COOT) fell 25.4% to $1.85 after falling over 22% on Friday.
    • Vimeo, Inc. (NASDAQ:VMEO) fell 26% to $3.98.
    • Aurora Mobile Limited (NASDAQ:JG) dipped 18.8% to $2.8428. Aurora Mobile announced plans to use Moonshot AI large language model in its AI bot creation platform, GPTBots.AI.
    • Invivyd, Inc. (NASDAQ:IVVD) fell 18.3% to $3.56. Invivyd shares jumped 41% on Friday after the company announced that PEMGARDA received emergency use authorization from the FDA for the pre-exposure prophylaxis of COVID-19.
    • Li-Cycle Holdings Corp. (NYSE:LICY) dipped 18.7% to $0.9181.
    • Aehr Test Systems (NASDAQ:AEHR) fell 18.1% to $12.01 after the company reported preliminary third-quarter and FY24 adjusted EPS and revenue results below estimates.
    • Bitcoin Depot Inc. (NASDAQ:BTM) fell 17.1% to $2.2216 following weak quarterly sales.
    • Invivyd, Inc. (NASDAQ:IVVD) declined 16.7% to $3.63.
    • Sonder Holdings Inc. (NASDAQ:SOND) fell 16.3% to $3.29.
    • Jowell Global Ltd. (NASDAQ:JWEL) fell 16.1% to $1.36.
    • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) fell 15.4% to $2.12 after dipping 31% on Friday.
    • Canopy Growth Corporation (NASDAQ:CGC) fell 13.1% to $6.68. The German government recently approved legislation which legalizes the possession and cultivation of cannabis beginning April 1.
    • Compass Minerals International, Inc. (NYSE:CMP) declined 13.1% to $15.25. US Forest Service halted contract with Compass Minerals for 2024 Fire Season due to safety concerns.
    • Yiren Digital Ltd. (NYSE:YRD) fell 12% to $4.46.
    • Dyne Therapeutics, Inc. (NASDAQ:DYN) dipped 11.8% to $24.90 after the company announced a CEO transition.
    • Open Lending Corporation (NASDAQ:LPRO) fell 10.3% to $6.41. Open Lending named Chuck Jehl as COO and Interim CEO.
    • Ontrak, Inc. (NASDAQ:OTRK) fell 10% to $0.3531 after jumping around 50% on Friday.
    • Laser Photonics Corporation (NASDAQ:LASE) shares fell 9.2% to $1.68 after dipping around 9% on Friday. Laser Photonics, last week, announced a distribution agreement with Incredible Supply & Logistics (ISL) for its military and industrial laser solutions.
    • OKYO Pharma Limited (NASDAQ:OKYO) shares fell 7.5% to $1.42 after falling around 13% on Friday. OKYO Pharma, last week, announced additional key findings from analyses of the clinical data set from the 240-patient Phase 2 trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED).

     

    Now Read This: Bitcoin Surpasses $67,000; Internet Computer Emerges As Top Gainer

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $AEHR
    $AKAN
    $BCAN

    CompanyDatePrice TargetRatingAnalyst
    Micron Technology Inc.
    $MU
    4/3/2026Buy → Hold
    Erste Group
    Micron Technology Inc.
    $MU
    4/2/2026Buy → Hold
    Erste Group
    Leidos Holdings Inc.
    $LDOS
    4/1/2026$165.00Equal Weight
    Wells Fargo
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Masimo Corporation
    $MASI
    3/27/2026Outperform → Mkt Perform
    Raymond James
    Sagimet Biosciences Inc.
    $SGMT
    3/26/2026$28.00Buy
    Rodman & Renshaw
    Micron Technology Inc.
    $MU
    3/19/2026Buy → Hold
    Summit Insights
    Micron Technology Inc.
    $MU
    3/19/2026$450.00 → $500.00Buy
    Needham
    More analyst ratings

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lucid Announces Q1 Production & Deliveries, Sets Date for First Quarter 2026 Results

    NEWARK, Calif., April 3, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced software-defined vehicles and technologies, today announced production and delivery totals for the quarter ended March 31, 2026. During this period, the company produced 5,500 vehicles and delivered 3,093 vehicles.1 During the quarter, deliveries of the Lucid Gravity were disrupted for 29 days due to a supplier quality issue with the second-row seats. As a result of this, the company's ability to meet customer demand was impacted. These issues have now been addresse

    4/3/26 5:00:00 PM ET
    $LCID
    Auto Manufacturing
    Industrials

    Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

    Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka's bempedoic acid products, together with related milestone payments, subject to a cap, for total consideration of $50 millionAthyrium Funds to receive tiered royalties ranging from 12% to 33%, as well as milestone payments, until receiving aggregate payments equal to 2.0x their investment, after which all rights revert to EsperionFinancing supports Esperion's acquisition of Corstasis Therapeutics Inc., which developed and is commercializing Enbumyst™, the first FDA-approved intranasal loop diuretic for treatment of edema associated with cardiovascular and hepatic and renal disease NEW YORK a

    4/2/26 4:05:00 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth – ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) (the Company) today announced the closing of its acquisition of Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular and hepatic and renal disease. "The closing of this acquisition marks an important milestone in advancing our Vision 2040 and strengthens our commitm

    4/2/26 4:00:00 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Arnzen April S

    4 - MICRON TECHNOLOGY INC (0000723125) (Issuer)

    4/3/26 7:01:39 PM ET
    $MU
    Semiconductors
    Technology

    SEC Form 4 filed by Moore Daniel William

    4 - GameStop Corp. (0001326380) (Issuer)

    4/3/26 5:11:59 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    SEC Form 4 filed by Robinson Mark Haymond

    4 - GameStop Corp. (0001326380) (Issuer)

    4/3/26 5:10:46 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Micron downgraded by Erste Group

    Erste Group downgraded Micron from Buy to Hold

    4/3/26 10:44:59 AM ET
    $MU
    Semiconductors
    Technology

    Micron downgraded by Erste Group

    Erste Group downgraded Micron from Buy to Hold

    4/2/26 9:25:13 AM ET
    $MU
    Semiconductors
    Technology

    Wells Fargo initiated coverage on Leidos with a new price target

    Wells Fargo initiated coverage of Leidos with a rating of Equal Weight and set a new price target of $165.00

    4/1/26 8:43:50 AM ET
    $LDOS
    EDP Services
    Technology

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    SEC Filings

    View All

    SEC Form 424B5 filed by Nkarta Inc.

    424B5 - Nkarta, Inc. (0001787400) (Filer)

    4/3/26 5:29:06 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lucid Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lucid Group, Inc. (0001811210) (Filer)

    4/3/26 5:06:01 PM ET
    $LCID
    Auto Manufacturing
    Industrials

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    4/3/26 4:09:21 PM ET
    $GDRX
    EDP Services
    Technology

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $38,700 worth of shares (2,000 units at $19.35), increasing direct ownership by 17% to 13,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/13/26 4:46:19 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    Financials

    Live finance-specific insights

    View All

    Lucid Announces Q1 Production & Deliveries, Sets Date for First Quarter 2026 Results

    NEWARK, Calif., April 3, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced software-defined vehicles and technologies, today announced production and delivery totals for the quarter ended March 31, 2026. During this period, the company produced 5,500 vehicles and delivered 3,093 vehicles.1 During the quarter, deliveries of the Lucid Gravity were disrupted for 29 days due to a supplier quality issue with the second-row seats. As a result of this, the company's ability to meet customer demand was impacted. These issues have now been addresse

    4/3/26 5:00:00 PM ET
    $LCID
    Auto Manufacturing
    Industrials

    MicroAlgo Announces Substantial Increase of 143.5% in Net Profit for 2025

    SHENZHEN, China, April 1, 2026 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ:MLGO), (the "Company"), a leading developer and application provider of bespoke central processing algorithms, today announced its financial results for the year ended December 31, 2025. Financial Highlights 2025The Company's net profit for 2025 was RMB 127.56 million (USD 18.15 million), representing a substantial increase of 143.5% compared with the same period of the prior year, demonstrating the Company's strong profitability.Diluted earnings per share for 2025 were RMB 14.87 (USD 2.12), compared with RMB 3.99 in 2024, representing an increase of 272.7%.Total shareholders' equity more than doubled, reaching RMB 2,321.8

    4/1/26 9:00:00 AM ET
    $MLGO
    EDP Services
    Technology

    AbbVie to Host First-Quarter 2026 Earnings Conference Call

    NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas

    3/31/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Bitcoin Depot Announces Executive Chair & CEO Transition; Names Alex Holmes as Chairman & CEO

    ATLANTA, March 24, 2026 (GLOBE NEWSWIRE) -- Bitcoin Depot (NASDAQ:BTM) ("Bitcoin Depot" or the "Company"), a U.S.-based Bitcoin ATM operator and fintech company, today announced that Scott Buchanan has decided to step down as Chief Executive Officer, effective immediately, to pursue a new opportunity outside of the Company. The board of directors thank Scott for his many contributions and wish him well in his next chapter. Effective immediately, Alex Holmes has been appointed Chief Executive Officer and Chairman of the Board. Holmes brings decades of executive leadership in global payments and fintech, most recently serving as Chairman and CEO of MoneyGram International, where he led the

    3/24/26 8:00:00 AM ET
    $BTM
    Finance: Consumer Services
    Finance

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABBV
    $AEHR
    $AKAN
    $BCAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care